Clusterstock  Mar 5  Comment 
Here's the hot new trend in Wall Street research note titles: emoticons.  From Piper Jaffray on Thursday: And we're having some fun with the title, but it's actually really apt! In results reported Wednesday after the close, Vanda's...
FierceBiotech  Mar 5  Comment 
Vanda's in-development eczema treatment failed to make a meaningful difference in a mid-stage trial, but the company isn't giving up, pointing to positive signs among a subset of patients.
Benzinga  Mar 4  Comment 
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced top-line results of the Phase II proof of concept clinical study investigating the safety and efficacy of tradipitant as a monotherapy in the treatment of chronic pruritus in...
TheStreet.com  Dec 30  Comment 
DELAFIELD, Wis. (Stockpickr) -- Corporate insiders sell their own companies' stock for a number of reasons. Must Read: Warren Buffett's Top 10 Dividend Stocks They might need the cash for a big personal purchase such as a new house or yacht, or...
Benzinga  Dec 23  Comment 
Among Tuesday's biggest gainers, there are a few with elevated short interest. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) The biopharmaceutical company focused on developing products for the treatment of the central nervous system sports a...
Benzinga  Dec 23  Comment 
NQ Mobile Inc (ADR) (NYSE: NQ) +27% - The company announced an $80 million repurchase program. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) +15% - Novartis AG announced it will make a $25 million investment in Vanda. China Finance Online Co....
Benzinga  Dec 23  Comment 
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) surged 19.06% to $14.18. The volume of Vanda Pharmaceuticals shares traded 952% higher than normal. Vanda Pharmaceuticals announced its plans to acquire rights to Phase II clinical compound from Novartis...
Benzinga  Dec 23  Comment 

You may also be interested in articles related to Vanda Pharmaceuticals (VNDA):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki